PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/643,801 Filing Date TRANSMITTAL August 18, 2003 **FORM** First Named Inventor Bhanot et al. Art Unit 1646 **Examiner Name** unassigned

Attorney Docket Number

(to be used for all correspondence after initial filing)

the date shown below:

Signature

Total Number of Pages in This Submission	4	Attorney Docket Number	RTS-0678	USA			
ENCLOSURES (Check all that apply)							
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks Customer No. 36441			After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name HOWSON AND HOWSON							
Signature May E. Bok							
Printed name Mary E. Bak							
Date October 8, 2004			Reg. No.	31,21	5		

October 8, 2004 Kelly A. Karstaedt Typed or printed name This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to Inis collection of information is required by 37 CFK 1.5. The information is required to obtain of retain a benefit by the public which is to life (and by the OSPTO) to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Kelly a Xarotusett

ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



RTS-0678USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/643,801 Confirmation No.: 4755

Applicant

: Bhanot et al.

Filed

: August 18, 2003

TC/A.U.

: 1646

Examiner

: unassigned

Customer No. : 36441

Title

: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE-2 EXPRESSION

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith. Information Disclosure Statement is submitted more than

Signature Xelly a Tanda of Kelly A. Karstaedt

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: October 8, 2004

three months from the filing date of this application but before the receipt of a first Office Action. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

REMARKS

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for Applicants

By Mary E Bak

Mary E Bak

Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477 Telephone: (215) 540-9200

Telefacsimile: (215) 540-5818



PTO/SB/08B (08-03)

Approved for use through 7/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known				
		Application Number	10/643,801			
INFORMATION DISCLOSURE			DISCLOSURE	Filing Date	August 18, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Bhanot et al.			
		Group Art Unit	1646			
(Use as many sheets as necessary)		Examiner Name	unassigned			
Sheet	1	of	1	Attorney Docket Number	RTS-0678USA	

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AL	CHENG et al., "Human acyl-CoA: diacylglycerol	
		acyltransferase is a tetrameric protein", Biochem. J. November 1, 2001 359(pt 3):707-714	
	AM	LUDWIG et al., "DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women", Clin. Genet. July 2002 62(1):68-73	
	AN	TABATA et al., "Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus", Phytochemistry October 1997 46(4):683-687	
	AO	TOMODA et al., "Roselipins, inhibitors of diacylglycerol acyltransferase, produced by Gliocladium roseum KF-1040", J. Antibiot. (Tokyo) August 1999 52(8):689-694	
	AP	YU et al., "Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes", J. Biol. Chem. December 27, 2002 277(52):50876-50884	
	_		
Part land			

Evaminar Signatura	Date
Examiner Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.